Next Steps in Non-Clear Cell Renal Cell Carcinoma Research
Thomas Hutson, DO, PharmD suggests the areas new research for non-clear cell renal cell carcinoma should explore.
Thomas Hutson, DO, PharmD, director of the Urologic Oncology Program and co-chair of the Urologic Cancer Research and Treatment Center at Baylor University Medical Center and professor of medicine, Texas A&M College of Medicine, suggests the areas new research for non-clear cell renal cell carcinoma (RCC) should explore.
According to Hutson, the next step in research for non-clear cell RCC should focus on further understanding the pathogenesis for each histologic subtype. While newer generation drugs such as lenvatinib (Lenvima) and everolimus (Zortress) show higher activity than earlier generation drugs, new targeted therapies are needed if the efficacy in non-clear cell RCC is ongoing to rival the efficacy seen in clear cell RCC.
Hutson says that these newer-generation drugs will most likely not be studied in large phase 3 trials as these histologies are rare. It would take years to accrue enough patients for regulatory approval, explains Hutson. The best thing to do, he says, is too keep researching and make the data publicly available to health care providers in order to help them make informed treatment decisions.
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Long-Term Ipi/Nivo RCC Data Show Durability Across Risk Groups
April 12th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the 8-year follow-up data of ipilimumab plus nivolumab in patients with advanced renal cell carcinoma In the first article of a 2-part series.
Read More
